Mylan B.v., Pharmaceutical Import Profile — Netherlands (DGFT 2022–2026)

Name: Mylan B.v., Pharmaceutical Import Records from India — 4 Products, $2.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mylan B.v., — Pharmaceutical Importer Profile (2026) | 4 Products, $2.2M Trade | TransData Nexus

Mylan B.v.,

Pharmaceutical Importer · Netherlands · Advanced Antibiotics Focus · $2.2M Total Trade · DGFT Verified

Mylan B.v., is a pharmaceutical importer based in Netherlands with a total trade value of $2.2M across 4 products in 3 therapeutic categories. Based on 55 verified import shipments from Indian Customs (DGFT) records, Mylan B.v., is the #1 buyer in 1 product including Lisinopril. Mylan B.v., sources from 8 verified Indian suppliers, with Mylan Laboratories Limited accounting for 63.1% of imports.

Mylan B.v., — Import Portfolio & Supplier Network

Mylan B.v., import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mylan B.v.,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$2.6M	153	63.1%
Medreich Limited	$481.3K	12	11.5%
Granules India Limited	$447.8K

What Formulations Does Mylan B.v., Import?

Formulation	Value	Ships
Metformine hcl viatris 500 MG 500s viatris # netherland pc464 metformine hcl mylan 500MG 500 tabl.	$182.0K	4
Gliclazide tablets 80 MG packs	$144.5K	3
Harmless medicines, duloxetine mylan 30MG 250bt cap 4,517	$140.9K	3
Flucloxacillin capsules BP 500MG	$100.0K	2
Eplerenone tablets 25MG eplerenone 25MG	$100.0K	2
Gliclazide retard mylan 30 MG 180bt	$100.0K	2
Esomeprazol mylan 40MG 100bt cap packs 100s bottle 9687 packs x 100s=968700	$100.0K	2
Oxybutynin hydrochloride tablets 2.5 MG	$87.7K	3
Harmless medicines, gliclazide retard mylan 30 MG 180bt 9,200	$64.7K	3
Oxybutynine hci mylan 2.5 MG TAB	$59.3K	2
Voriconazol mylan 200 MG 30bl TAB	$56.3K	2
Sulfasalazine mylan 500MG sulfasalazine500mg Pack 1x90t b no az11322 422 522 622 722 822 mfg dec 2022 exp dec	$50.0K	1
Harmless medicines simvastatine mylan 40 MG 1000bt TAB 8668	$50.0K	1
Simvastatine mylan 40 MG 1000bt TAB packs	$50.0K	1
Pantoprazol mylan 20MG 90bt TAB packs	$50.0K	1

Mylan B.v., imports 161 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Flucloxacillin	Advanced Antibiotics	$1.4M	30	2.4%	6
2	Enalapril	Cardiovascular	$318.5K	14	0.1%	14
3	Sulfasalazine	Gastrointestinal	$308.2K	8	3.1%	6
4	Lisinopril	Cardiovascular	$150.0K	3	0.2%	1

Mylan B.v., imports 4 pharmaceutical products across 3 categories into Netherlands totaling $2.2M. The company is the #1 buyer for 1 product: Lisinopril.

Mylan B.v., — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mylan B.V. is a pharmaceutical importer and buyer based in the Netherlands, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company is headquartered at Krijgsman 20, 1186 DM, Amstelveen, Netherlands. Established in 1999, Mylan B.V. operates within the wholesale trade services of pharmaceutical products sector. As a subsidiary of Viatris, a global healthcare company formed in November 2020 through the merger of Mylan and Upjohn, Mylan B.V. plays a significant role in the Netherlands' pharmaceutical distribution network.

2Distribution Network

Mylan B.V. maintains a centralized distribution model, importing pharmaceutical products primarily from India. The company's logistics operations are managed from its headquarters in Amstelveen, facilitating the importation and distribution of pharmaceutical formulations across the Netherlands. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's strategic position in Amstelveen suggests efficient access to major transportation routes, enabling effective distribution throughout the country.

3Industry Role

In the Netherlands' pharmaceutical supply chain, Mylan B.V. functions as a primary wholesaler, sourcing finished pharmaceutical formulations from international suppliers and distributing them within the domestic market. The company's focus on importing finished products indicates its role in bridging international manufacturers with local healthcare providers, ensuring the availability of a diverse range of medications to meet domestic demand.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mylan B.v.,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mylan B.V. exhibits a high degree of sourcing concentration, with a total import value of $2.2 million USD from India across 55 shipments. The top five imported products—Flucloxacillin, Enalapril, Sulfasalazine, Lisinopril, and Amoxicillin—account for 100% of the company's imports, indicating a focused product portfolio. This concentration suggests a strategic choice to streamline operations and leverage supplier relationships, potentially enhancing negotiation power and supply chain efficiency. However, such dependency on a limited number of suppliers and products may pose risks related to supply disruptions or market fluctuations.

2Supply Chain Resilience

Mylan B.V.'s supply chain resilience is closely tied to its reliance on Indian suppliers, particularly Mylan Laboratories Limited, which accounts for 63.1% of the total import value. The company's import portfolio includes 161 unique formulations, indicating a diverse range of products sourced from India. While this diversity may mitigate risks associated with single-product dependency, the heavy reliance on a few key suppliers could expose the company to supply chain vulnerabilities. The resilience of Mylan B.V.'s supply chain is contingent upon the stability and reliability of its Indian suppliers, necessitating robust contingency planning and supplier diversification strategies.

Importing Pharmaceuticals into Netherlands — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Netherlands

1Regulatory Authority & Framework

In the Netherlands, the Dutch Medicines Evaluation Board (CBG) is the primary regulatory authority overseeing the evaluation and supervision of medicines. The Medicines Act (Geneesmiddelenwet) serves as the key legislation governing pharmaceutical imports, ensuring that all medicinal products meet safety, efficacy, and quality standards before entering the market. For Indian generics to be marketed in the Netherlands, they must undergo a centralized marketing authorization procedure through the European Medicines Agency (EMA), which evaluates applications for medicinal products intended for the European Union market.

2Import Licensing & GMP

Import licensing requirements in the Netherlands stipulate that pharmaceutical importers must hold a wholesale distribution authorization issued by the CBG. This authorization ensures that importers comply with Good Distribution Practice (GDP) standards, maintaining the quality and integrity of medicinal products throughout the supply chain. Regarding Good Manufacturing Practice (GMP), the Netherlands recognizes certifications from the European Union (EU GMP), World Health Organization (WHO GMP), and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Indian exporters seeking to supply Mylan B.V. must ensure that their manufacturing facilities hold valid GMP certifications from these recognized bodies to meet regulatory standards.

Mylan B.v., — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mylan B.V.'s product strategy focuses on importing finished pharmaceutical formulations in the therapeutic categories of Advanced Antibiotics, Cardiovascular, and Gastrointestinal. The company's top five imported products—Flucloxacillin, Enalapril, Sulfasalazine, Lisinopril, and Amoxicillin—align with these categories, indicating a strategic emphasis on addressing prevalent health conditions in the Netherlands. Market demand for these medications is driven by the need for effective treatments for infections, cardiovascular diseases, and gastrointestinal disorders, reflecting the company's responsiveness to public health needs.

2Sourcing Profile

Mylan B.V. employs a sourcing strategy that prioritizes finished pharmaceutical formulations, particularly generic drugs, from India. This approach leverages India's robust pharmaceutical manufacturing capabilities and cost advantages. The company's focus on specific therapeutic areas suggests a targeted procurement strategy aimed at meeting the therapeutic needs of the Dutch market. India's established reputation for producing high-quality generics positions it as a key supplier in Mylan B.V.'s overall procurement strategy.

3Market Positioning

Seller's Guide — How to Become a Supplier to Mylan B.v.,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Mylan B.V., particularly those offering high-quality generic formulations in the therapeutic areas of Advanced Antibiotics, Cardiovascular, and Gastrointestinal treatments. Gaps in Mylan B.V.'s current sourcing may exist in terms of product variety or specific formulations not currently imported. Indian exporters can explore these opportunities by aligning their product offerings with Mylan B.V.'s strategic focus and ensuring compliance with regulatory standards.

2Requirements & Qualifications

Indian exporters seeking to supply Mylan B.V. and the Netherlands market must ensure that their manufacturing facilities hold valid GMP certifications from recognized bodies such as EU GMP, WHO GMP, or PIC/S. Additionally, products must meet batch testing, stability, and labeling requirements, with labeling in Dutch and adherence to serialization mandates. Compliance with these standards is essential to gain access to the Dutch pharmaceutical market and establish a partnership with Mylan B.V.

3How to Approach

Frequently Asked Questions — Mylan B.v.,

What products does Mylan B.v., import from India?

Mylan B.v., imports 4 pharmaceutical products across 3 categories. Top imports: Flucloxacillin ($1.4M), Enalapril ($318.5K), Sulfasalazine ($308.2K), Lisinopril ($150.0K).

Who supplies pharmaceuticals to Mylan B.v., from India?

Mylan B.v., sources from 8 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (63.1% of imports, $2.6M).

What is Mylan B.v.,'s total pharmaceutical import value?

Mylan B.v.,'s total pharmaceutical import value from India is $2.2M, based on 55 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mylan B.v., focus on?

Mylan B.v., imports across 3 categories. The largest: Advanced Antibiotics (63.9%), Cardiovascular (21.7%), Gastrointestinal (14.3%).

Get Full Mylan B.v., Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 7 company name variants from customs records. For current shipment-level data, contact TransData Nexus.